Goodwin Procter LLP advised Inflazome on the deal. Inflazome announced its acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) for an upfront consideration of €380 million….
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
